US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Tvardi Therapeutics Inc

3.99

-0.0600-1.48%

Post-market: 3.990.00000.00%16:15 EST

Volume:42.18K

Turnover:169.92K

Market Cap:37.43M

PE:-0.51

High:4.16

Open:4.00

Low:3.95

Close:4.05

52wk High:43.65

52wk Low:3.50

Shares:9.38M

Float Shares:7.78M

Volume Ratio:1.04

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-7.8700

EPS(LYR):-4.5947

ROE:-135.64%

ROA:-72.68%

PB:1.34

PE(LYR):-0.87

Loading ...

Overview Company News Filings

Analysts’ Top Healthcare Picks: Inhibikase Therapeutics (IKT), Tvardi Therapeutics (TVRD)

Foghorn Therapeutics Names Ryan Maynard Chief Financial Officer

Tvardi Therapeutics to Present at Major Healthcare Investor Conferences

Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases

BRIEF-Tvardi Therapeutics Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% Placebo

Tvardi Therapeutics Inc - Topline Healthy Volunteer Data From Phase 1 Study of Next-Generation Stat3 Inhibitor, Tti-109, on Track for H1 2026

THOMSON REUTERS

Tvardi Therapeutics Reports Phase 2 Data Showing TTI-101 Reduces Fibrosis in IPF Patients

Tvardi Therapeutics Approves New Severance and Retention Compensation Plan for Executives

Tvardi Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Tvardi Therapeutics Faces Financial Hurdles Amidst Ongoing Product Development Challenges

Tvardi Therapeutics reports third quarter 2025 results and updates on clinical programs

Tvardi Therapeutics Inc - Qtrly Shr Loss $0.59

THOMSON REUTERS

Tvardi Therapeutics- on Track for Topline Data From Phase 2 Trial of Tti-101 in Hepatocellular Carcinoma (Hcc) in H1 2026

THOMSON REUTERS

Press Release: Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics to Present at Jefferies Global Healthcare Conference in London

Tvardi Therapeutics Inc : Raymond James Cuts to Market Perform From Outperform

THOMSON REUTERS

Tvardi Therapeutics : Barclays Cuts to Equal-Weight From Overweight

THOMSON REUTERS

Tvardi Therapeutics Inc : Btig Cuts Target Price to $15 From $55

THOMSON REUTERS

Oppenheimer Reaffirms Their Buy Rating on Tvardi Therapeutics (TVRD)

Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TVRD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":3.99,"timestamp":1772226000000,"preClose":4.05,"halted":0,"volume":42175,"hourTrading":{"tag":"盘后","latestPrice":3.99,"preClose":3.99,"latestTime":"16:15 EST","volume":1845,"amount":7360.2760275,"timestamp":1772226926293,"change":0,"changeRate":0,"amplitude":0.000251},"delay":0,"changeRate":-0.014814814814814718,"floatShares":7778729,"shares":9381344,"eps":-7.87,"marketStatus":"Post-Mkt","change":-0.06,"latestTime":"02-27 16:39:05 EST","open":4,"high":4.1583,"low":3.95,"amount":169921.8216,"amplitude":0.051432,"askPrice":4.44,"askSize":100,"bidPrice":3.99,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-7.87,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772240400000},"marketStatusCode":4,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":4.05,"preHourTrading":{"tag":"盘前","latestPrice":3.8455,"preClose":4.05,"latestTime":"08:25 EST","volume":757,"amount":2921.932945,"timestamp":1772198757622,"change":-0.2045,"changeRate":-0.050494,"amplitude":0.00358},"postHourTrading":{"tag":"盘后","latestPrice":3.99,"preClose":3.99,"latestTime":"16:15 EST","volume":1845,"amount":7360.2760275,"timestamp":1772226926293,"change":0,"changeRate":0,"amplitude":0.000251},"volumeRatio":1.04144,"impliedVol":2.9005,"impliedVolPercentile":0.7458},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":7778729,"roa":"-72.68%","roe":"-135.64%","lyrEps":-4.594733,"volumeRatio":1.04144,"shares":9381344,"dividePrice":0,"high":4.1583,"amplitude":0.051432,"preClose":4.05,"low":3.95,"week52Low":3.5,"pbRate":"1.34","week52High":43.65,"institutionHeld":0,"latestPrice":3.99,"committee":-0.941748,"eps":-7.87,"divideRate":0,"volume":42175,"delay":0,"ttmEps":-7.87,"open":4,"prevYearClose":4.3,"prevWeekClose":3.64,"prevMonthClose":3.97,"prevQuarterClose":4.3,"fiveDayClose":3.64,"twentyDayClose":3.9,"sixtyDayClose":3.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"TVRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.83,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2025-08-14","symbol":"TVRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":1},{"market":"US","date":"2025-05-13","symbol":"TVRD","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-3.22},{"market":"US","date":"2025-04-16","symbol":"TVRD","defaultRemindTime":1744810200000,"type":"split","dateTimestamp":1744776000000,"forFactor":3,"toFactor":1,"ratio":3},{"market":"US","date":"2025-03-11","symbol":"TVRD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.25,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":8,"updateTime":1770699600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVRD","date":"2026-02-26","current":-0.506989,"percent":0.897959,"low":-17.054928,"twenty":-11.756711,"median":-1.836912,"eighty":-1.57665,"high":-1.408431,"avg":-5.38903,"sd":5.217706,"marketCap":36118174},"quantilePoints":[{"date":"2025-08-01","current":-6.984237,"twenty":-7.018674,"median":-6.984237,"eighty":-6.867475,"marketCap":242869870},{"date":"2025-08-08","current":-6.220168,"twenty":-7.05634,"median":-6.986928,"eighty":-6.651705,"marketCap":216300131},{"date":"2025-08-15","current":-6.400424,"twenty":-7.003609,"median":-6.690985,"eighty":-6.397734,"marketCap":222568344},{"date":"2025-08-22","current":-10.573024,"twenty":-9.576632,"median":-6.986928,"eighty":-6.42948,"marketCap":249861702},{"date":"2025-08-29","current":-12.013447,"twenty":-10.759129,"median":-7.048807,"eighty":-6.480866,"marketCap":283901784},{"date":"2025-09-05","current":-12.078921,"twenty":-11.588463,"median":-7.134899,"eighty":-6.493511,"marketCap":285449060},{"date":"2025-09-12","current":-14.047103,"twenty":-11.928926,"median":-9.803211,"eighty":-6.612426,"marketCap":331961128},{"date":"2025-09-19","current":-15.372451,"twenty":-12.457478,"median":-10.666275,"eighty":-6.823352,"marketCap":363281754},{"date":"2025-09-26","current":-14.606606,"twenty":-13.432046,"median":-11.499578,"eighty":-6.955181,"marketCap":345183308},{"date":"2025-10-03","current":-14.82882,"twenty":-14.620891,"median":-11.737664,"eighty":-6.987466,"marketCap":350434671},{"date":"2025-10-10","current":-17.054928,"twenty":-14.850248,"median":-11.943013,"eighty":-6.991233,"marketCap":403042070},{"date":"2025-10-17","current":-2.571334,"twenty":-14.850248,"median":-11.769409,"eighty":-6.823352,"marketCap":60765765},{"date":"2025-10-24","current":-2.047544,"twenty":-14.833582,"median":-11.58886,"eighty":-6.422216,"marketCap":48387554},{"date":"2025-10-31","current":-1.849138,"twenty":-14.74787,"median":-11.130543,"eighty":-4.843171,"marketCap":43698837},{"date":"2025-11-07","current":-1.563435,"twenty":-14.662953,"median":-10.195062,"eighty":-2.595143,"marketCap":36947086},{"date":"2025-11-14","current":-1.631573,"twenty":-14.620891,"median":-9.523459,"eighty":-2.06421,"marketCap":38557323},{"date":"2025-11-21","current":-1.515552,"twenty":-14.489944,"median":-7.06764,"eighty":-1.887232,"marketCap":35836734},{"date":"2025-11-28","current":-1.634574,"twenty":-14.266143,"median":-6.990963,"eighty":-1.811838,"marketCap":38651137},{"date":"2025-12-05","current":-1.658378,"twenty":-13.805842,"median":-6.911597,"eighty":-1.667399,"marketCap":39214017},{"date":"2025-12-12","current":-1.781368,"twenty":-13.436014,"median":-6.493242,"eighty":-1.662637,"marketCap":42122234},{"date":"2025-12-19","current":-1.543324,"twenty":-13.412999,"median":-6.400424,"eighty":-1.660082,"marketCap":36493428},{"date":"2025-12-26","current":-1.5949,"twenty":-13.32332,"median":-6.349307,"eighty":-1.639335,"marketCap":37713002},{"date":"2026-01-02","current":-1.705987,"twenty":-13.031267,"median":-2.777676,"eighty":-1.642509,"marketCap":40339779},{"date":"2026-01-09","current":-1.678216,"twenty":-12.62652,"median":-2.62292,"eighty":-1.634574,"marketCap":39683085},{"date":"2026-01-16","current":-1.789303,"twenty":-12.344784,"median":-2.448323,"eighty":-1.634574,"marketCap":42309861},{"date":"2026-01-23","current":-1.91626,"twenty":-12.181298,"median":-2.07532,"eighty":-1.634574,"marketCap":45311891},{"date":"2026-01-30","current":-1.547291,"twenty":-12.091222,"median":-1.95231,"eighty":-1.634574,"marketCap":36587241},{"date":"2026-02-06","current":-1.408431,"twenty":-12.026542,"median":-1.896756,"eighty":-1.617117,"marketCap":33303771},{"date":"2026-02-13","current":-1.475877,"twenty":-11.900753,"median":-1.8627,"eighty":-1.598129,"marketCap":34898599},{"date":"2026-02-20","current":-1.424301,"twenty":-11.810677,"median":-1.847154,"eighty":-1.590139,"marketCap":33679024},{"date":"2026-02-26","current":-1.527454,"twenty":-11.756711,"median":-1.836912,"eighty":-1.57665,"marketCap":36118174}],"updateTime":1772228345539},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVRD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613329867","title":"Analysts’ Top Healthcare Picks: Inhibikase Therapeutics (IKT), Tvardi Therapeutics (TVRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613329867","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613329867?lang=en_us&edition=fundamental","pubTime":"2026-02-24 04:01","pubTimestamp":1771876883,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inhibikase Therapeutics (IKT – Research Report) and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-inhibikase-therapeutics-ikt-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-inhibikase-therapeutics-ikt-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LABU","XLV","LU0029874061.USD","BK4581","BK4007","BK4139","HCSG","IKT","BK4585","XBI","BK4588","LU0128526141.USD","TVRD"],"gpt_icon":0},{"id":"2613890237","title":"Foghorn Therapeutics Names Ryan Maynard Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2613890237","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613890237?lang=en_us&edition=fundamental","pubTime":"2026-02-23 20:00","pubTimestamp":1771848031,"startTime":"0","endTime":"0","summary":"Foghorn Therapeutics Inc. appointed Ryan Maynard as Chief Financial Officer, effective February 23, 2026. Maynard previously served as CFO at Cara Therapeutics and has more than 25 years of experience in biopharmaceutical finance and strategic transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foghorn Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL10K2qn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","BK4007","BK4588","SG9999014005.SGD","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD","FHTX","LU2210150020.SGD","BK4139","SG9999014013.SGD","TVRD"],"gpt_icon":0},{"id":"2610634929","title":"Tvardi Therapeutics to Present at Major Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2610634929","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610634929?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:03","pubTimestamp":1770901381,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing small molecule therapies targeting STAT3 for fibrosis-driven diseases, has announced its participation in several upcoming investor conferences. These include the JonesTrading C-Suite Fireside Chat Series on Wednesday, February 19, 2026, at 11:00 AM EST ; the Oppenheimer 36th Annual Healthcare Life Sciences Conference with a corporate presentation on Wednesday, February 25, 2026, at 10:40 AM EST ; the TD Cowen 46th Annual Health Care Conference with a corporate presentation on Tuesday, March 3, 2026, at 1:50 PM EST in Boston, MA; and the Barclays 28th Annual Global Healthcare Conference with a fireside chat on Tuesday, March 10, 2026, at 2:00 PM EST in Miami Beach, FL. Webcasts of the JonesTrading fireside chat and Oppenheimer presentation will be accessible on the Tvardi Investors' website, with replays available for approximately 90 days following the conferences.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL6MZ5rY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0171281750.USD","LU1064927863.SGD","LU0345770993.USD","LU1078025761.USD","BARC.UK","LU0161305163.EUR","LU0345777147.USD","LU0345777659.USD","LU0964806797.USD","BK5152","LU0550127509.SGD","LU0987226296.USD","BK4007","LU0047473722.EUR","LU0048578792.EUR","LU0997586606.USD","LU1023061473.USD","LU0345770308.USD","LU1668664300.SGD","LU0047473722.SGD","LU1791807156.HKD","TVRD","LU1023061713.HKD","LU1035777561.USD","LU0106831901.USD","LU2646069778.SGD"],"gpt_icon":0},{"id":"2603934475","title":"Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2603934475","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603934475?lang=en_us&edition=fundamental","pubTime":"2026-01-16 08:04","pubTimestamp":1768521893,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc. has released a new corporate presentation highlighting progress in its development of therapies targeting STAT3 biology for fibrosis-driven diseases and cancers. The company reports demonstrated target engagement and disease modification across animal models, as well as observed reductions in fibrosis and inflammation markers in clinical studies. Tvardi’s lead program, TTI-101, is being evaluated for idiopathic pulmonary fibrosis  and hepatocellular carcinoma , with additional data from ongoing trials expected in the near term. The presentation also notes the advancement of TTI-109, a prodrug designed to enhance delivery and tolerability of STAT3 inhibition, currently in a Phase 1 trial with healthy volunteers. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLbkMQfs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2601362494","title":"BRIEF-Tvardi Therapeutics Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2601362494","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601362494?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:35","pubTimestamp":1767879304,"startTime":"0","endTime":"0","summary":"BRIEF-Tvardi Therapeutics Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% PlaceboJan 8 (Reuters) - Tvardi Therapeutics Inc TVRD.O:TVARDI THERAPEUTICS INC - TTI-101 SHOWS 9.4% FIBROSIS SCORE DEC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2601364234","title":"Tvardi Therapeutics Inc - Topline Healthy Volunteer Data From Phase 1 Study of Next-Generation Stat3 Inhibitor, Tti-109, on Track for H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364234?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:11","pubTimestamp":1767877894,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90F9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2601364566","title":"Tvardi Therapeutics Reports Phase 2 Data Showing TTI-101 Reduces Fibrosis in IPF Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364566","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364566?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:02","pubTimestamp":1767877372,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc. has announced further updates from its Phase 2 REVERT IPF clinical trial evaluating TTI-101, an oral STAT3 inhibitor, in patients with idiopathic pulmonary fibrosis . Data from the study, which was previously announced as not meeting its primary endpoints in October 2025, include additional analyses on a subset of 40 patients who completed 12 weeks of treatment. The results show a 9.4% decrease from baseline in fibrosis score for patients treated with TTI-101, compared to a 2.4% decrease in the placebo group. Additionally, 63% of patients in the TTI-101 group experienced an increase in forced vital capacity  at 12 weeks, versus 46% in the placebo group. The company has also stated that topline healthy volunteer data from a Phase 1 study of its next-generation STAT3 inhibitor, TTI-109, is expected in the first half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL8W0KM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2095319765.USD","IE00BKPKM429.USD","TVRD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2592182225","title":"Tvardi Therapeutics Approves New Severance and Retention Compensation Plan for Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182225","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182225?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:21","pubTimestamp":1766096514,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc. has approved a one-time retention compensation package for its named executive officers. Chief Executive Officer Dr. Imran Alibhai received an option to purchase 47,500 shares, while Chief Medical Officer Dr. John Kauh and Chief Financial Officer Dan Conn each received options for 17,500 shares. The options have an exercise price based on the closing per-share price on the grant date, with 25% of the shares vesting on the one-year anniversary of December 16, 2026, and the remainder vesting in equal monthly installments over the next three years. Additionally, the company adopted a Severance and Change in Control Plan providing severance and equity vesting acceleration benefits to eligible employees, including the named executive officers, in the event of certain qualifying terminations.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL8gmB5d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2584293721","title":"Tvardi Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584293721","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584293721?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:03","pubTimestamp":1763471017,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The company's management will also host one-on-one investor meetings during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on November 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL5DkFbS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","BK4127","TVRD","BK4007"],"gpt_icon":0},{"id":"2583652586","title":"Tvardi Therapeutics Faces Financial Hurdles Amidst Ongoing Product Development Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2583652586","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583652586?lang=en_us&edition=fundamental","pubTime":"2025-11-16 14:00","pubTimestamp":1763272856,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc. (TVRD) has disclosed a new risk, in the Accounting & Financial Operations category. Tvardi Therapeutics Inc. faces signifi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tvardi-therapeutics-faces-financial-hurdles-amidst-ongoing-product-development-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tvardi-therapeutics-faces-financial-hurdles-amidst-ongoing-product-development-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","TVRD","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2583178511","title":"Tvardi Therapeutics reports third quarter 2025 results and updates on clinical programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2583178511","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583178511?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:02","pubTimestamp":1763067728,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc. reported cash, cash equivalents and short-term investments of $36.5 million as of September 30, 2025, up from $31.6 million at December 31, 2024. Research and development expenses for the third quarter of 2025 were $3.6 million, a decrease from $4.8 million in the same period of 2024, primarily due to lower costs related to TTI-101 trials and the completion of the IPF trial in the second quarter of 2025. These decreases were partially offset by a $2.0 million increase in expenses associated with the healthy volunteer study of TTI-109. Tvardi stated that its current cash runway is expected to fund operations into the fourth quarter of 2026. The company continues to advance its Phase 2 study of TTI-101 in hepatocellular carcinoma, with topline data expected in the first half of 2026, and has initiated a healthy volunteer study for TTI-109, with results also anticipated in the first half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL5l44wY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2583996512","title":"Tvardi Therapeutics Inc - Qtrly Shr Loss $0.59","url":"https://stock-news.laohu8.com/highlight/detail?id=2583996512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583996512?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA9G64BH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2583129675","title":"Tvardi Therapeutics- on Track for Topline Data From Phase 2 Trial of Tti-101 in Hepatocellular Carcinoma (Hcc) in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583129675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583129675?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA9G64BH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2583904511","title":"Press Release: Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583904511","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583904511?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067660,"startTime":"0","endTime":"0","summary":"On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma  in H1 2026. Results from healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, expected in H1 2026. Tvardi Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today announced its nancial and operating results for the third quarter ended September 30, 2025, and provided a business update.--  Continued to progress its Phase 2 study of TTI-101 in HCC, with topline. TTI-109, is in effect and that a healthy volunteer study has been. \"To that end, we eagerly await data from our ongoing Phase 2 REVERT Liver Cancer trial in the first half of next year. Interim results from this study have already shown clinically meaningful activity of TTI-101 both as monotherapy and in combination with established anti-cancer agents across treatment lines.Phase 1b/2 clinical tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HCC","BK4007","LENZ","BK4006","TVRD"],"gpt_icon":0},{"id":"2580173488","title":"Tvardi Therapeutics to Present at Jefferies Global Healthcare Conference in London","url":"https://stock-news.laohu8.com/highlight/detail?id=2580173488","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580173488?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:02","pubTimestamp":1762261336,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025. The company's management will also host investor one-on-one meetings during the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLbKn22T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2575292196","title":"Tvardi Therapeutics Inc : Raymond James Cuts to Market Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2575292196","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575292196?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:40","pubTimestamp":1760442046,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nFWN3VV1VF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2575267569","title":"Tvardi Therapeutics : Barclays Cuts to Equal-Weight  From Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2575267569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575267569?lang=en_us&edition=fundamental","pubTime":"2025-10-14 16:52","pubTimestamp":1760431943,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nAZN4NUEZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2575572702","title":"Tvardi Therapeutics Inc : Btig Cuts Target Price to $15 From $55","url":"https://stock-news.laohu8.com/highlight/detail?id=2575572702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575572702?lang=en_us&edition=fundamental","pubTime":"2025-10-14 13:23","pubTimestamp":1760419425,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nFWN3VV107:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2575233964","title":"Oppenheimer Reaffirms Their Buy Rating on Tvardi Therapeutics (TVRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2575233964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575233964?lang=en_us&edition=fundamental","pubTime":"2025-10-14 05:15","pubTimestamp":1760390119,"startTime":"0","endTime":"0","summary":"In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Tvardi Therapeutics, with a price target of $10.00. The company’s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-tvardi-therapeutics-tvrd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-tvardi-therapeutics-tvrd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVRD","OPY"],"gpt_icon":0},{"id":"2575328444","title":"Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks","url":"https://stock-news.laohu8.com/highlight/detail?id=2575328444","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575328444?lang=en_us&edition=fundamental","pubTime":"2025-10-14 02:23","pubTimestamp":1760379780,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/13/Medical--Research-And-Scientist-In-Labor_0.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/13/Medical--Research-And-Scientist-In-Labor_0.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/10/48184263/tvardi-therapeutics-lung-disease-candidate-fails-to-show-any-clinical-benefit-stock-sinks","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48184263/tvardi-therapeutics-lung-disease-candidate-fails-to-show-any-clinical-benefit-stock-sinks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LENZ","TVRD","BK4139","FVC","BK4539","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}